Global Cancer Stem Cell Therapeutics Market Report 2019-2023 - ResearchAndMarkets.com

DUBLIN--()--The "Global Cancer Stem Cell Therapeutics Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.

The global cancer stem cell therapy market is forecast to grow at a CAGR of over 11% during the forecast period.

Cancer is one of the most common causes of deaths across the world. The high prevalence of various types of cancer, such as breast cancer, bladder cancer, lung cancer, leukemia, pancreatic cancer, and prostate cancer, has increased the mortality rate across the world.

Countries such as Hungary, Netherlands, Denmark, and Croatia have witnessed an increase in the number of cancer cases over the past few years. The growing instances of cancer-related morbidity across the world will fuel the demand for cancer stem cell therapeutics.

Strong drug pipeline

The prevalence of cancer across the world is driving many vendors in the market to develop novel stem cell therapies. Several drugs are in the late stages of clinical trials and are expected to receive marketing approvals over the forecast period. For instance, CanStem 303C is an orally administered drug developed to inhibit cancer cell pathways in patients with metastatic pancreatic ductal adenocarcinoma. The drug is currently in Phase III of clinical trials and is expected to be launched in the US by 2021.

Side-effects of stem cell transplant

Stem cell transplant causes several immediate side effects such as fatigue, vomiting, low levels of platelets and red blood cells, and diarrhea. It may also cause several long term effects such as infertility, eye disorders, early menopause, lung and bone damage, and risk of developing other cancer types. These risk factors may hinder the growth of the global cancer stem cell therapy market size.

Competitive Landscape

The market appears to be fairly concentrated with few players occupying the market share. Companies such as Cellerant Therapeutics & Celularity, have intensified competition. Factors such as the rising prevalence of cancer and the strong drug pipeline will provide significant growth opportunities for cancer stem cell therapy companies.

Key Players

  • Cellerant Therapeutics Inc.
  • Celularity Inc.
  • Gamida Cell Ltd.
  • Nohla Therapeutics Inc.
  • Sumitomo Dainippon Pharma Co. Ltd.

Topics Covered

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY TYPE

  • Comparison by type
  • Allogeneic stem cell transplant - Market size and forecast 2018-2023
  • Autologous stem cell transplant - Market size and forecast 2018-2023
  • Market opportunity by type

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • RoW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

PART 11: MARKET TRENDS

  • Increasing research activity on cancer stem cell key signaling pathways
  • Availability of stem cell markers in the identification of cancer stem cells
  • Development of first-in-class therapeutics using induced pluripotent stem cells

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Cellerant Therapeutics Inc.
  • Celularity Inc.
  • Gamida Cell Ltd.
  • Nohla Therapeutics Inc.
  • Sumitomo Dainippon Pharma Co. Ltd.

For more information about this report visit https://www.researchandmarkets.com/r/ymptib

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Oncology Drugs , Stem Cells

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Oncology Drugs , Stem Cells